CVBF is pleased to announce a strategic leadership evolution that marks an exciting new chapter in the company’s growth. Mariagrazia Felisi has been appointed as the new Chief Executive Officer, effective from the 30th of January 2026, succeeding Donato Bonifazi, who has led the organization as CEO since the 10th of January 2012.

Mariagrazia brings a wealth of institutional knowledge and proven leadership to her new role, having been with CVBF since its inception in 2000. Over more than two decades, she has grown alongside the company, contributing to its success across key strategic areas and demonstrating exceptional versatility and commitment.

Throughout her tenure, Mariagrazia has held various important roles within the organization, long serving as Head of Quality Assurance and subsequently expanding her leadership as Clinical Research Director. In these positions, she has been instrumental in establishing robust management systems, ensuring regulatory compliance, and driving excellence in clinical trial execution. Her deep understanding of both the operational and strategic dimensions of the business positions her uniquely to lead CVBF into its next phase of growth.

This appointment represents the culmination of years of dedication, continuous professional development, and demonstrated leadership capability. Mariagrazia’s assumption of greater responsibility reflects CVBF’s commitment to nurturing talent from within and recognizing those who have contributed to building the company’s strong foundation.

Donato Bonifazi, who has successfully steered CVBF as CEO for almost 15 years, will step into the visionary role of Strategy Leader. In this capacity, he will spearhead company-wide growth initiatives centered on CVBF’s strategic mission in paediatric and rare disease development. His focus will encompass strengthening pan-European networks, advancing an innovative strategic approach to clinical trials acceleration, and bridging the critical gap between academic research and patient care; leveraging CVBF’s distinctive position as a modern, agile CRO that combines operational excellence with competitive efficiency, professional rigor, and unwavering ethical standards.

This strategic realignment allows CVBF to leverage Donato’s extensive experience and stakeholders relationships in shaping long-term vision and identifying new avenues for expansion, while empowering fresh leadership to guide day-to-day operations and implement innovative approaches.

The leadership evolution comes at a pivotal moment for CVBF as the organization continues to expand its capabilities and strengthen its position in the clinical research landscape. Mariagrazia’s appointment signals continuity paired with renewed energy and perspective, ensuring that CVBF remains agile and responsive to evolving market demands.

“This evolution represents a natural progression for our organization,” Donato suggested. “Mariagrazia’s deep expertise, proven track record, and intimate understanding of our culture and values make her the ideal leader to guide CVBF forward. We are confident that under her leadership, the company will continue to thrive and achieve new milestones.”

CVBF looks forward to this new chapter and remains committed to delivering excellence in clinical research while fostering innovation and sustainable growth.